People who have amyotrophic lateral sclerosis (ALS) deserve the attention and energy of our best researchers.
With knowledge and greater understanding comes the potential to find new medicines to treat ALS. Here are some facts that are already known about the disease.
Although a lot is still unknown about ALS, some facts are clear.
ALS is a disease that causes muscle weakness throughout the body. The disease is progressive, which means it gets worse over time, but how fast it acts varies from person to person.3
There are many helpful resources that people who have ALS and their families can turn to for detailed information about the disease. Several local and national support groups also exist and can be found online.
No one knows exactly how ALS starts, but dysregulation of the immune system may exacerbate the disease.
Studies have suggested that a problem with the immune system may play a role in ALS. Specifically, one part of the immune system that helps fight infections in the body—called the complement system—may be damaging healthy cells instead. We believe that this knowledge points toward the complement system as a potential target of medical intervention.4
At Ra Pharma, we are committed to advancing research in ALS.
We believe the key to finding a treatment for ALS may lie in exploring the role of the complement system in the disease. Beyond our curiosity as scientists, our commitment to our research is driven by our conviction that people with ALS and their families warrant better treatment options as soon as possible.
References: 1. ALS Association. ALS Association About ALS page. ALS Association Web Site. http://www.alsa.org/about-als. Accessed August 27, 2019. 2. ALS Therapy Development Institute. ALS Therapy Development Institute Web Site. https://www.als.net . Accessed August 27, 2019. 3. Mehta P, Kaye W, Raymond J, et al. Prevalence of amyotrophic lateral sclerosis—United States, 2014. MMWR Morb Mortal Wkly Rep. 2018;67:216-218. 4. Sta M, Sylva-Steenland RM, Casula M, et al. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis. 2011;42(3):211-220.